Why Acadia (ACAD) Could Beat Earnings Estimates Again

Group 1 - Acadia Pharmaceuticals has a strong history of beating earnings estimates, with an average surprise of 87.50% over the last two quarters [1] - In the most recent quarter, Acadia reported earnings of $0.20 per share, exceeding the expected $0.16 per share by 25%, and in the previous quarter, it reported $0.10 per share against an estimate of $0.04 per share, resulting in a surprise of 150% [1] - Recent estimates for Acadia have been moving higher, with a positive Zacks Earnings ESP indicating a strong potential for another earnings beat [2][3] Group 2 - The Zacks Earnings ESP for Acadia is currently +0.92%, suggesting that analysts have recently become more optimistic about the company's earnings prospects [3] - The combination of a positive Earnings ESP and a Zacks Rank 1 (Strong Buy) indicates a high likelihood of another earnings beat for Acadia [3] - Stocks with a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better have a nearly 70% chance of producing a positive surprise [2]